Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab and Gemcitabine in Relapsed or Refractory DLBCL
NCT00216164Phase 2Terminated
- Sponsor
- Hoosier Cancer Research Network
- Start
- Apr 2005
- Primary completion
- Mar 2007
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, gemcitabine in diffuse large B-cell lymphoma (DLBCL), sponsored by Hoosier Cancer Research Network. Started Apr 2005; status: terminated.
02
Drugs
rituximabgemcitabine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00216164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00216164.